Johnson & Johnson (JNJ) Earnings Date & Reports

Key Takeaways

• Revenue reached $25.31 billion in Q2 2026, up 6.6% year-over-year and ahead of the consensus estimate of approximately $25.02 billion.
• Adjusted earnings per share (EPS) came in at $2.90, beating analyst expectations of roughly $2.86 by $0.04 and rising 4.7% from the prior-year period.
• Innovative Medicine posted operational sales growth of 6.8%, driven by standout performances from TREMFYA, DARZALEX, CARVYKTI, and other oncology and immunology therapies, more than offsetting a sharp decline in STELARA due to biosimilar competition.
• MedTech grew 3.6% on an operational basis to $8.93 billion, though the segment slightly missed expectations amid softness in Abiomed and competitive pressure in electrophysiology.
• Full-year guidance was raised: the company now expects adjusted EPS of $11.60 to $11.75 and revenue of $100.8 billion to $101.4 billion, putting Johnson & Johnson on track to exceed $100 billion in annual sales for the first time in its 140-year history.
• Stock reaction was muted to negative, with shares declining roughly 2% on July 15 as MedTech concerns overshadowed the broader beat-and-raise quarter.

Earnings Context and Why It Matters

Johnson & Johnson's Q2 2026 report, released on July 15, carried heightened significance for several reasons. As the first major pharmaceutical and healthcare company to report each earnings season, J&J often sets the tone for the broader drug and biotech sector. The quarter also represented a pivotal moment in the company's multi-year effort to navigate the patent cliff on STELARA, its former blockbuster immunology drug, while simultaneously scaling its next generation of oncology, immunology, and neuroscience therapies. With the stock trading near all-time highs of $269 ahead of the report and up roughly 22% year-to-date, expectations were elevated. Investors were looking for confirmation that J&J's pipeline momentum could sustain above-market growth and deliver on its ambition of crossing the $100 billion annual revenue threshold in 2026.

Reported Results

Johnson & Johnson reported worldwide second-quarter sales of $25.31 billion, reflecting reported growth of 6.6% and operational growth of 5.6% compared to the same period a year ago. This exceeded Wall Street consensus estimates, which had called for revenue of roughly $25.02 billion. On an adjusted operational basis — which excludes the impact of currency translation and acquisitions and divestitures — sales grew 5.7%.

On the bottom line, the company posted GAAP diluted EPS of $2.27, compared to $2.29 in Q2 2025. Adjusted diluted EPS, which strips out intangible amortization and special items, rose to $2.90 from $2.77 a year ago, representing a 4.7% increase. The adjusted figure comfortably beat the consensus analyst estimate of approximately $2.86.

Segment-level results told a nuanced story. The Innovative Medicine division — which encompasses J&J's pharmaceutical portfolio — generated $16.4 billion in worldwide sales, with operational growth of 6.8%. This performance was particularly impressive given an approximate 760-basis-point headwind from STELARA, which declined 55.7% as biosimilar competition eroded its market position. Excluding STELARA, the Innovative Medicine business grew in double digits. Standout performers included TREMFYA (up 71%), CARVYKTI (up 47.7%), TECVAYLI (up 56.1%), TALVEY (up 62.6%), RYBREVANT plus LAZCLUZE (up 61.6%), SPRAVATO (up 40%), and CAPLYTA (up 70.9%). DARZALEX, J&J's largest product, delivered another quarter of more than $4 billion in sales, growing close to 18%.

The MedTech segment reported sales of $8.93 billion, with operational growth of 3.6%. While surgery, vision, and orthopaedics all expanded, the cardiovascular sub-segment grew just 3.1% — slower than recent trends. Electrophysiology was pressured by competitive dynamics in pulsed field ablation (PFA) and China inventory headwinds, while Abiomed posted a 2% decline after a U.K. clinical trial raised questions about Impella device usage in certain high-risk procedures, prompting more selective physician adoption. Shockwave remained a bright spot with double-digit growth of 14.7%.

AI Screener

For investors seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool allows traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Whether screening for breakout candidates, trending stocks, or fundamentally strong companies within specific sectors like healthcare, the AI Screener helps users surface trade ideas and market opportunities with greater speed and precision than manual research. Exploring the screener can complement your earnings-season workflow by highlighting names that may warrant deeper analysis.

Market Reaction and Investor Sentiment

Despite delivering a beat on both revenue and earnings and raising full-year guidance, Johnson & Johnson shares slipped approximately 2% to 2.7% on July 15, closing at $247.02. The decline reflected a mix of profit-taking following the stock's strong year-to-date run and disappointment over the MedTech segment's underperformance relative to expectations. Analysts at RBC Capital Markets noted that MedTech sales missed the Street's forecast by roughly $660 million, while oncology product sales also came in slightly light. The Abiomed contraction, in particular, raised questions about near-term growth momentum in the cardiovascular portfolio. Still, the broader analyst community remained constructive, with several firms characterizing the pullback as a potential entry opportunity given the underlying strength of the pharmaceutical pipeline and the company's consistent track record of exceeding earnings expectations — now stretching across five consecutive quarters.

Forward Outlook and Key Factors to Monitor

Looking ahead, Johnson & Johnson's raised guidance for full-year 2026 signals management's confidence in sustaining momentum through the second half. The company now projects adjusted EPS of $11.60 to $11.75 and total revenue of $100.8 billion to $101.4 billion. Achieving the midpoint of the revenue range would mark the first time in J&J's 140-year history that annual sales surpass $100 billion — a significant milestone likely to attract institutional attention.

Several factors will shape the trajectory from here. First, the pace of STELARA erosion remains a critical variable; while the company has successfully offset the decline with new products so far, any acceleration in biosimilar adoption could pressure the Innovative Medicine growth rate. Second, the MedTech division's ability to stabilize Abiomed will be closely watched. Management has indicated that the U.K. clinical trial headwind is temporary and expects modest growth from Abiomed in the second half, but definitive clarity may not arrive until the PROTECT IV trial data is presented in 2027.

On the positive side, J&J's pipeline continues to deliver. Recent approvals for TREMFYA in psoriatic arthritis, CAPLYTA in schizophrenia relapse prevention, and the Dual Energy THERMOCOOL SMARTTOUCH SF platform in electrophysiology add to an already robust growth story. The company also received a permanent J-code for INLEXZO, its bladder cancer therapy, which should improve patient access and reimbursement. With the planned Enterprise Business Review scheduled for December 8, 2026, investors can expect additional strategic clarity before year-end.

Cost management and margin trends also warrant attention. While R&D expenses leveraged favorably in Q2, selling and marketing costs deleveraged due to investment in new product launches. Tariffs introduced incremental pressure in the MedTech supply chain, and litigation-related expenses weighed on other income. Balancing growth investment against margin discipline will remain a central theme as J&J advances toward its target of double-digit revenue growth by the end of the decade.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations